MAPT and Alzheimer disease: Several new blood‐based biomarkers (BBMs) of Alzheimer's disease (AD) and related neuropathologies have completed late‐stage validation and are beginning to be used in clinical care, augmenting existing AD biomarkers that test cerebrospinal fluid (CSF) or employ positron emission tomography (PET) to detect the amyloid plaques and tau tangles in AD.1